Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease

British Journal of Cancer

Volumn 113, Issue 3, 2015, Pages 460-468

  Reis, I M ^a,b   Ramachandran, K ^a   Speer, C ^a   Gordian, E ^a   Singal, R ^a,b,c  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADD45A; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; DNA; GADD45A PROTEIN, HUMAN; NUCLEAR PROTEIN;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; DNA METHYLATION; GLEASON SCORE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION INITIATION SITE; BLOOD; DIFFERENTIAL DIAGNOSIS; GENETICS; PREDICTIVE VALUE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

BIOMARKERS, TUMOR; CELL CYCLE PROTEINS; DIAGNOSIS, DIFFERENTIAL; DNA; DNA METHYLATION; HUMANS; MALE; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 84938409095     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.240     Document Type: Article

References (46)

1. Andriole GL, Crawford ED, Grubb 3rd RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13): 1310-1319.
2. Bastian PJ, Palapattu GS, Yegnasubramanian S, Rogers CG, Lin X, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG (2008) CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J Urol 179(2): 529-534.
3. Breiman L, Freidman J, Olshen R, Stone C (1984) Classification and Regression Trees. Wadsworth: Belmont, CA, USA.
4. Chang CP, Chia RH, Wu TL, Tsao KC, Sun CF, Wu JT (2003) Elevated cell-free serum DNA detected in patients with myocardial infarction. Clin Chim Acta 327(1-2): 95-101.
5. Das PM, Ramachandran K, Vanwert J, Ferdinand L, Gopisetty G, Reis IM, Singal R (2006) Methylation mediated silencing of TMS1/ASC gene in prostate cancer. Mol Cancer 5: 28.
6. Ellinger J, Bastian PJ (2010) Cell-free DNA: a novel biomarker for patients with prostate cancer? Open Prost Cancer J 3: 57-62.
7. Ellinger J, Haan K, Heukamp LC, Kahl P, Buttner R, Muller SC, von Ruecker A, Bastian PJ (2008) CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate 68(1): 42-49.
8. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94(13): 981-990.
9. Flamini E, Mercatali L, Nanni O, Calistri D, Nunziatini R, Zoli W, Rosetti P, Gardini N, Lattuneddu A, Verdecchia GM, Amadori D (2006) Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin Cancer Res 12(23): 6985-6988.
10. Garzotto M, Beer TM, Hudson RG, Peters L, Hsieh YC, Barrera E, Klein T, Mori M (2005) Improved detection of prostate cancer using classification and regression tree analysis. J Clin Oncol 23(19): 4322-4329.
11. Goering W, Kloth M, Schulz WA (2012) DNA methylation changes in prostate cancer. Methods Mol Biol 863: 47-66.
12. Goessl C, Krause H, Muller M, Heicappell R, Schrader M, Sachsinger J, Miller K (2000) Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 60(21): 5941-5945.
13. Goessl C, Muller M, Heicappell R, Krause H, Miller K (2001) DNA-based detection of prostate cancer in blood, urine, and ejaculates. Ann N Y Acad Sci 945: 51-58.
14. Gonzalgo ML, Jones PA (1997) Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). Nucleic Acids Res 25(12): 2529-2531.
15. Gordian E, Ramachandran K, Reis IM, Manoharan M, Soloway MS, Singal R (2010) Serum free circulating DNA is a useful biomarker to distinguish benign versus malignant prostate disease. Cancer Epidemiol Biomarkers Prev 19(8): 1984-1991.
16. Heinze G (2006) A comparative investigation of methods for logistic regression with separated or nearly separated data. Stat Med 25(24): 4216-4226.
17. Heinze G, Schemper M (2002) A solution to the problem of separation in logistic regression. Stat Med 21(16): 2409-2419.
18. Heyn H, Esteller M (2012) DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 13(10): 679-692.
19. Hoque MO (2009) DNA methylation changes in prostate cancer: current developments and future clinical implementation. Expert Rev Mol Diagn 9(3): 243-257.
20. Marsit CJ, Koestler DC, Christensen BC, Karagas MR, Houseman EA, Kelsey KT (2011) DNA methylation array analysis identifies profiles of blood-derived DNA methylation associated with bladder cancer. J Clin Oncol 29(9): 1133-1139.
21. Mychaleckyj JC, Farber EA, Chmielewski J, Artale J, Light LS, Bowden DW, Hou X, Marcovina SM (2011) Buffy coat specimens remain viable as a DNA source for highly multiplexed genome-wide genetic tests after long term storage. J Transl Med 9: 91.
22. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL (1995) Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 154(2 Pt 1): 407-413.
23. Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz EA, Nelson WG, De Marzo AM (2003) Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol 163(3): 923-933.
24. Okkonen M, Lakkisto P, Korhonen AM, Parviai-nen I, Reinikainen M, Varpula T, Pettila V. FINNALI Study Group (2011) Plasma cell-free DNA in patients needing mechanical ventilation. Crit Care 15(4): R196.
25. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh PC (1990) Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143(4): 747-752.
26. Ramachandran K, Gopisetty G, Gordian E, Navarro L, Hader C, Reis IM, Schulz WA, Singal R (2009) Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target. Cancer Res 69(4): 1527-1535.
27. Ramachandran K, van Wert J, Gopisetty G, Singal R (2007) Developmentally regulated demethylase activity targeting the betaA-globin gene in primary avian erythroid cells. Biochemistry 46(11): 3416-3422.
28. Reibenwein J, Pils D, Horak P, Tomicek B, Goldner G, Worel N, Elandt K, Krainer M (2007) Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance. Prostate 67(4): 427-432.
29. Ren N, Qin LX, Tu H, Liu YK, Zhang BH, Tang ZY (2006) The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 132(6): 399-407.
30. Royo JL, Hidalgo M, Ruiz A (2007) Pyrosequencing protocol using a universal biotinylated primer for mutation detection and SNP genotyping. Nat Protoc 2(7): 1734-1739.
31. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13): 1320-1328.
32. Shapiro B, Chakrabarty M, Cohn EM, Leon SA (1983) Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 51(11): 2116-2120.
33. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1): 5-29.
34. Silva JM, Dominguez G, Garcia JM, Gonzalez R, Villanueva MJ, Navarro F, Provencio M, San Martin S, Espana P, Bonilla F (1999) Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res 59(13): 3251-3256.
35. Smith DS, Humphrey PA, Catalona WJ (1997) The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience. Cancer 80(9): 1852-1856.
36. Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, Roz E, Cirenei N, Bellomi M, Pelosi G, Pierotti MA, Pastorino U (2003) Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 21(21): 3902-3908.
37. Suga Y, Miyajima K, Oikawa T, Maeda J, Usuda J, Kajiwara N, Ohira T, Uchida O, Tsuboi M, Hirano T, Kato H, Ikeda N (2008) Quantitative p16 and ESR1 methylation in the peripheral blood of patients with non-small cell lung cancer. Oncol Rep 20(5): 1137-1142.
38. Sunami E, Shinozaki M, Higano CS, Wollman R, Dorff TB, Tucker SJ, Martinez SR, Mizuno R, Singer FR, Hoon DS (2009) Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem 55(3): 559-567.
39. Taback B, O'Day SJ, Hoon DS (2004) Quantification of circulating DNA in the plasma and serum of cancer patients. Ann N Y Acad Sci 1022: 17-24.
40. Therneau T, Atkinson B, Ripley B (2014) rpart: Recursive Partitioning and Regression Trees p R package version 4.1-9 Available from http://CRAN.R-project.org/package=rpart.
41. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman Jr CA (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level oor =4.0 ng per milliliter. N Engl J Med 350(22): 2239-2246.
42. van der Vaart M, Pretorius PJ (2008) Circulating DNA. Its origin and fluctuation. Ann N Y Acad Sci 1137: 18-26.
43. Wong IH, Lo YM, Yeo W, Lau WY, Johnson PJ (2000) Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin Cancer Res 6(9): 3516-3521.
44. Wu TL, Zhang D, Chia JH, Tsao KH, Sun CF, Wu JT (2002) Cell-free DNA: measurement in various carcinomas and establishment of normal reference range. Clin Chim Acta 321(1-2): 77-87.
45. Yang M, Park JY (2012) DNA methylation in promoter region as biomarkers in prostate cancer. Methods Mol Biol 863: 67-109.
46. You YJ, Chen YP, Zheng XX, Meltzer SJ, Zhang H (2012) Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients. Cancer Lett 315(2): 138-144.